DUBLIN--(BUSINESS WIRE)--The "Breast Cancer Liquid Biopsy Market Research Report by Biomarker, by End-User - United States Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The United States Breast Cancer Liquid Biopsy Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation.
Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Breast Cancer Liquid Biopsy Market.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the United States Breast Cancer Liquid Biopsy Market including Biodesix, Inc., FLUXION BIOSCIENCES, GUARDANT HEALTH, INC, Isogen Life Science, and Thermo Fisher Scientific Inc..
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward.
The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
Key Topics Covered:
2. Research Methodology
3. Executive Summary
3.1. Market Outlook
3.2. Biomarker Outlook
3.3. End-User Outlook
3.4. Competitor Outlook
4. Market Overview
5. Market Dynamics
6. United States Breast Cancer Liquid Biopsy Market, By Biomarker
6.2. Cell-free DNA (cfDNA)
6.3. Circulating Tumor Cells (CTCs)
6.4. Extracellular Vesicles (EVs)
6.5. Other Circulating Biomarkers
7. United States Breast Cancer Liquid Biopsy Market, By End-User
7.2. Hospitals & Physician Laboratories
7.3. Reference Laboratories
8. Competitive Strategic Window
8.2. Competitive Strategic Window, by Biomarker
8.3. Competitive Strategic Window, by End-User
9. Competitive Landscape
9.1. FPNV Positioning Matrix
9.1.2. Business Strategy
9.1.3. Product Satisfaction
9.2. Market Ranking Analysis
9.3. Market Share Analysis
9.4. Competitive Scenario
9.4.1. Merger & Acquisition
9.4.2. Agreement, Collaboration, & Partnership
9.4.3. New Product Launch & Enhancement
9.4.4. Investment & Funding
9.4.5. Award, Recognition, & Expansion
10. Company Usability Profiles
10.1. Biodesix, Inc.
10.2. FLUXION BIOSCIENCES
10.3. GUARDANT HEALTH, INC
10.4. Isogen Life Science
10.5. Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/6cwwpp